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For patients with unfavorable or high-risk prostate cancer, dose escalated radiation
therapy leads to improved progression free survival but attempts to deliver increased
dose by external beam radiation therapy (EBRT) alone can be limited by late toxicities
to nearby genitourinary and gastrointestinal organs at risk. Brachytherapy is a method
to deliver dose escalation in conjunction with EBRT with a potentially improved late
toxicity profile and improved prostate cancer related outcomes. At least three randomized
controlled trials have demonstrated improved biochemical control with the addition of
either low-dose rate (LDR) or high-dose rate (HDR) brachytherapy to EBRT, although
only ASCENDE-RT compared brachytherapy to dose-escalated EBRT but did report an
over 50% improvement in biochemical failure with a LDR boost. Multiple single institution
and comparative research series also support the use of a brachytherapy boost in the
DE-EBRT era and demonstrate excellent prostate cancer specific outcomes. Despite
improved oncologic outcomes with a brachytherapy boost in the high-risk setting, the
utilization of both LDR, and HDR brachytherapy use is declining. The acute genitourinary
toxicities when brachytherapy boost is combinedwith EBRT, particularly a LDR boost, are
of concern in comparison to EBRT alone. HDR brachytherapy boost has many physical
properties inherent to its rapid delivery of a large dose which may reduce acute toxicities
and also appeal to the radiobiology of prostate cancer. We herein review the evidence
for use of either LDR or HDR brachytherapy boost for high-risk prostate cancer and
summarize comparisons between the two treatment modalities.
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INTRODUCTION
Nearly 180,000 new cases of prostate cancer are estimated to be diagnosed in 2019 (1, 2).
For patients with high-risk prostate cancer, treatment options most often include surgery or
a combination of androgen deprivation therapy (ADT) and radiation therapy. External beam
radiation therapy (EBRT) is the most common method to deliver radiotherapy for localized
prostate cancer.Multiple studies have demonstrated that dose-escalated external beam radiation
Fischer-Valuck et al. Brachytherapy Boost High-Risk Prostate Cancer
therapy (DE-EBRT) improves local control, freedom from
biochemical failure, freedom from distance metastases, and
decreases the need for salvage therapy (3–6). DE-EBRT, however,
has also been associated with increases in late genitourinary
(GU) and gastrointestinal (GI) toxicities (3). In the NRG
Oncology/RTOG 0126 randomized clinical trial, the 5-years rates
of both GI and GU late toxicity were increased with dose
escalation (3). Brachytherapy is a method to deliver high-dose
radiotherapy and escalate the biologically equivalent dose (BED),
either as monotherapy or in tandem with EBRT as a boost,
which is highly conformal and can often provide sparing of
the surrounding organs at risk that is often not achievable with
EBRT. Both permanent seed low dose-rate (LDR) or high dose-
rate (HDR) brachytherapy provide a highly conformal escalation
of dose to the cancer and allow greater sparing of surrounding
normal organs than that possible with any type of EBRT (7).
The American Society of Clinical Oncology (ASCO)/Cancer
Care Ontario (CCO) Joint Guideline Update published in
2017 explicitly states that for patients with high-risk prostate
cancer receiving EBRT and androgen deprivation therapy (ADT),
brachytherapy boost (either LDR or HDR) should be offered
to eligible patients (8). This recommendation is largely based
on the ASCENDE-RT trial which demonstrated a significant
improvement in the rates of biochemical relapse for patients
treated with a brachytherapy boost (9). In ASCENDE-RT, the
brachytherapy boost was delivered using a permanent seed low-
dose rate (LDR) implant. LDR brachytherapy is a proven method
with decades of follow-up and endorsement by numerous expert
consensus groups. Another method of brachytherapy, high-dose
rate (HDR) brachytherapy, is an alternative to LDR which has
many properties that may make it a superior alternative to
LDR. In contrast to LDR, HDR is not a permanent implant and
generally allows for more consistent dose coverage and relative
lower dose to the rectum, bladder, and urethra (7, 10, 11). Both
LDR and HDR boost are recommended in the ASCO/CCO
Joint Guideline recommendations and the choice between the
two is often determined by physician, hospital, patient, and
disease characteristics. We herein report on the importance of
the brachytherapy boost as well as compare and contrast the
use of both LDR and HDR brachytherapy as a boost in high-
risk prostate cancer, and summarize future directions using these
treatment modalities.
LDR BRACHYTHERAPY BOOST
LDR brachytherapy, commonly referred to as permanent
prostate brachytherapy or seed implant, is a type of procedure
in which implanted radioactive sources are permanently placed
into the prostate. Defined by the International Commission on
Radiologic Units and Measurements, LDR brachytherapy is the
utilization of a radiation source with a dose-rate of <2Gy per
hour (12). Brachytherapy boost delivered with LDR has been
a well-established treatment modality in the treatment of high-
risk prostate cancer with numerous studies supporting its use
and efficacy (13–15). Sathya et al. (16) conducted a randomized
controlled trial comparing EBRT to 40Gy in 20 fractions plus
a temporary LDR brachytherapy boost with iridium-192–35Gy
vs. EBRT alone to 66Gy in 33 fractions in patients with high-
risk prostate cancer. No androgen deprivation therapy was
given neoadjuvantly or concurrently in either arm. The primary
outcome was biochemical or clinical failure. With a median
follow-up of 8.2 years, 29% of patients in the EBRT plus
temporary LDR brachytherapy boost arm failed vs. 61% in the
EBRT alone arm (hazard ratio, 0.42; p = 0.0024) (16, 17). While
the EBRT dose used in this study was low compared to modern
standards, this trial laid the groundwork and confirmed the
principal that brachytherapy in conjunction with moderate dose
EBRT resulted in increased rates of biochemical control than that
achieved with EBRT alone.
Recently, the highly anticipated results of a large randomized
trial comparing the now standard dose-escalated EBRT to EBRT
plus LDR brachytherapy boost were published. The ASCENDE-
RT trial was a randomized Phase III study comparing EBRT
alone (78 Gy/39 fractions) to EBRT (46 Gy/23 fractions) plus
an LDR brachytherapy boost (115Gy using 125I) in patients
with intermediate or high-risk prostate cancer (9). Both arms
included 12 months of androgen deprivation therapy. The trial
included 398 patients and demonstrated a statistically significant
improvement in biochemical progression-free survival (b-PFS)
in favor of the brachytherapy boost arm, with 9-years b-PFS of
83 vs. 62% (18). At a median follow-up of 6.5 years, there was no
statistical difference in 7-years overall survival although there was
a trend toward improvement with the LDR boost (85.7 vs. 81.5%).
Longer follow-up of the trial will be necessary to determine if the
addition of the LDR-boost correlates to improved metastasis free,
cause-specific, and overall survival with these results anticipated
with median follow-up of 13 years. With regards to overall
survival, Johnson et al. (19) identified patients from the National
Cancer Database (NCDB) with unfavorable prostate cancer who
were treated with either DE-EBRT or EBRT with a LDR boost.
This study attempted tomirror enrollment criteria of ASCENDE-
RT but allowed patients to have received ADT up to 8 months
prior to definitive radiation therapy. They found that the LDR
boost was associated with improved overall survival (7-years OS
82 vs. 73%; p < 0.001) (19). The improved survival outcome
persisted in multivariable analysis and with propensity score
matching, although the study cannot fully account for selection
bias in the choice of treatment.
HDR BOOST
HDR differs from LDR in that radiation sources with higher
activity are temporarily inserted into the prostate gland using
catheter needles and then removed after the prescribed dose has
been delivered. The International Commission on Radiologic
Units and Measurements defines HDR as a dose delivered at
a rate >12 Gy/h, although in actuality this is usually much
higher, often in excess of 1Gy per minute (7, 12). With
regards to radiation biology, the degree of dose escalation
achievable with HDR brachytherapy, compared to other EBRT
techniques and LDR, may be more effective in killing prostate
cancer cells (7, 20, 21). The rapid dose delivery seen in
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HDR is considered to be selectively more damaging to cells
with lower alpha/beta ratios, such as prostate cancer and late
responding normal tissues (22–24). Radiobiologic models thus
support current clinical evidence for equivalent outcomes with
either LDR or HDR, with theoretical advantages to HDR
brachytherapy (22).
In terms of HDR brachytherapy boost, there does exist at
least one randomized trial although it predates DE-EBRT. Hoskin
et al. (25) performed a randomized controlled trial of a HDR
boost vs. EBRT alone in patients with mostly intermediate
and high-risk disease (25). Patients were randomized to receive
either EBRT alone (55 Gy/20 fractions) or EBRT (35.75 Gy/13
fractions) plus an HDR boost (17 Gy/2 fractions). Neoadjuvant
androgen deprivation therapy was given in 76% of patients at
the discretion of the treating physician. Men in the HDR boost
cohort had a 31% decrease in the risk of local recurrence, and late
genitourinary toxicities were similar in both arms (7, 25). Despite
providing randomized evidence, criticisms of this trial include a
low EBRT alone radiation dose (55 Gy/20 fractions) compared
to current standards of 60Gy in 20 fractions or 78–80Gy
in standard fractionation. A randomized feasibility study was
conducted by Vigneault et al. to assess the ability to randomize
patients between dose escalated image-guided radiation therapy
(IGRT) (78 Gy/39 fractions or 60 Gy/20 fractions) and IGRT
plus HDR brachytherapy boost (37.5 Gy/15 fractions + 15Gy
HDR boost) with good compliance although small numbers (57
patients randomized) (26). Rates of protocol deviations and acute
toxicities were low in both arms, but no biochemical control rates
are reported as data matures (26).
While no other prospective, randomized comparisons of DE-
EBRT and HDR boost exist, multiple single institution reports
have demonstrated favorable biochemical control rates similar to
those in ASCENDE-RT with better toxicity profiles. Vigneault
et al. (27) reported on a cohort of 832 men with intermediate
and high-risk disease treated with a range of doses of HDR
brachytherapy boost in combination with EBRT and found
biochemical control of 95% with median follow-up of 66 months
(27). In this trial, they reported that late grade 3 GU toxicity
ranged from∼2–5% dependent on the dose level the patient was
treated on (27). There were no grade 3 GI toxicities reported.
Androgen suppression was used in 41.3% of patients in this
study (4–6 months in intermediate cases and 18–36 months in
high-risk cases). There was significant differences in the median
follow-up between the different HDR dose levels which did
not allow for valid comparison of biochemical control rates
between the different groups. Martinez et al. reported on a dose
escalation trial using a HDR brachytherapy boost and found
very favorable 10-years PSA control approaching 81% in men
receiving the escalated dose treatment (28). Of the over 470
patients treated with EBRT plus HDR, grade 3 genitourinary
toxicity was extremely rare at <1% (28). Neoadjuvant and/or
concurrent androgen suppression was used in 51.3% of the
patients. Additional data is also emerging in support of an
HDR boost in the high-risk setting. Kent et al. (29) recently
published results of their single institution retrospective review
of 46Gy EBRT plus HDR boost (median boost 18 Gy/3
fractions) compared to EBRT alone (median 70Gy). The 5, 10,
and 15-years overall survival was higher at 92, 81, and 67%,
respectively, for the EBRT plus HDR cohort, compared with
88, 71, and 53%, respectively, in the EBRT alone cohort (p
< 0.001) (29). The 5, 10, and 15-years cause specific survival
was also higher in the HDR boost group with survival of
96, 93, and 87% (EBRT plus HDR) and 95, 88, and 79%
(EBRT alone), respectively (p < 0.037) (29). A limitation of
this study is the heterogenous use of androgen suppression
at the discretion of the treating physician and specifically an
increased use of ADT in the EBRT plus HDR group. Also, a
median dose of 70Gy by standard fractionation in the external
beam alone group is again lower than the current standard for
dose escalated therapy. Numerous other single institution trials
also support the use of HDR brachytherapy boost (11, 30–34)
(Supplemental Methods).
HDR Vs. LDR BOOST
Multiple studies have suggested that when used in the
monotherapy setting for more favorable localized prostate
cancer, both HDR and LDR brachytherapy have equivalent
biochemical progression-free survival outcomes (35, 36). For
high-risk patients, the 2017 American Society of Clinical
Oncology (ASCO)/Cancer Care Ontario (CCO) brachytherapy
guidelines state that men with high-risk prostate cancer should
be offered either an LDR or HDR boost if choosing a definitive
radiation management approach (8). The recommendation of
a brachytherapy boost was largely based on the previously
discussed three randomized controlled trials comparing EBRT
alone to EBRT plus a brachytherapy boost and demonstrate
improved disease free survival with the boost (Table 1).
In each of these trials, however, a different modality/type
of brachytherapy boost was used. Data comparing LDR
and HDR head-to-head are much more limited in the
boost setting.
For men with high-risk disease, Kishan et al. (37) reported
on the differences in prostate cancer-specific mortality and
distant metastasis in prostate cancer patients with high-
risk disease treated with either surgery, EBRT with ADT,
or EBRT plus either LDR or HDR brachytherapy with
ADT in a large multi-institutional cohort (37). Androgen
deprivation therapy was given in 89.5% of patients receiving
EBRT alone and 92.4% of patients receiving EBRT plus
brachytherapy boost (37). The duration of androgen suppression
was significantly shorter in the EBRT plus brachytherapy arm
(12 vs. 22 months EBRT alone; p < 0.001) (37). Despite the
difference in androgen suppression duration, this study found
that among patients with Gleason 9–10 disease, treatment
with EBRT plus brachytherapy and ADT was associated
with significantly better prostate cancer-specific mortality and
longer time to distant metastases compared to surgery or
ADT and EBRT alone (37). They performed a cause-specific
regression to determine an effect of LDR vs. HDR on clinical
outcomes, including both prostate cancer-specific mortality and
distant metastasis, and found no difference between the two
techniques (37).
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TABLE 1 | Randomized controlled trials comparing external beam radiation therapy (EBRT) vs. EBRT plus brachytherapy boost.
RCT Year Treatment #Patients Primary
outcome
OS PCSM MFSR
Sathya14 1992–1997 EBRT 53 BCF: 39% NR NR NR
EBRT + LDR 51 BCF: 71%
Hoskin23 1997–2005 EBRT 111 bDFS: 4.3 y 88%, 7 y NR NR
EBRT + HDR 109 bDFS: 5.1 y 81%, 7 y
p = 0.04 p = 0.2
Morris6 2002–2011 DE-EBRT 200 bDFS: 62%, 9 y 74%, 7 y 5.5% 9%
EBRT + LDR 198 bDFS: 83%, 9 y 78%, 7 y 3.5% 8.5%
p < 0.001 p = 0.29 p = 0.32 p = 0.83
RCT, randomized controlled trial; OS, overall survival; PCSM, prostate cancer specific mortality; MFSR, metastasis free survival rate; EBRT, external beam radiation therapy; LDR, low
dose rate brachytherapy; HDR, high dose rate brachytherapy; BCF, biochemical failure; bDFS, biochemical disease free survival.
King et al. (38) used the National Cancer Database in
an attempt to compare LDR vs. HDR boost with regards
to overall survival outcomes. In their study, they estimated
overall survival in patients with unfavorable prostate cancer
treated with dose-escalated EBRT and EBRT followed by LDR
boost vs. HDR boost (38). Patients included were diagnosed
with NCCN intermediate or high-risk prostate cancer from a
time period of 2004–2014. In their analysis of over 120,000
patients, HDR boost was associated with a similar overall
survival compared to LDR boost using multivariable analysis
[adjusted hazard ratio (AHR), 1.03 (0.96–1.11); p = 0.38].
Compared to dose-escalated EBRT, HDR boost was associated
with significantly better overall survival [AHR, 1.36 (1.29–
1.44); p < 0.001] (38). Androgen deprivation therapy was given
in 40.4% of patients with the HDR boost, 43.1% of patients
with the LDR boost, and 49% of patients with DE-EBRT
(p < 0.001) (38).
TOXICITY CONCERNS
RTOG P-0019 was a phase II study of EBRT combined with
LDR brachytherapy boost (45Gy/25 fractions + 108Gy 125I
boost) for intermediate risk prostate cancer with the primary
goal to estimate the acute and late Grade 3-5 GU and GI
toxicity (39). Short-term androgen suppression up to 6 months
was allowed and 27% received ADT. A total of 138 patients
from 28 institutions were enrolled on the study with acute
toxicity evaluable in 131 patients (39). Acute Grade 3 GU
toxicity was recorded in 7.6% of patients without any Grade
4 or 5 events (39). Six months after radiation therapy, ∼63%
of patients reported a higher International Prostate Symptom
Score (IPSS) score compared to baseline (39). The 18-months
estimate of both late Grade 3 GU and GI toxicity was 3.3% (39).
With longer follow-up, increased rates of Grade 3 or greater
GU/GI toxicity were reported, estimated at 15% (95% CI, 8–
21%) at 48 months (40). CALGB 99809 was another multi-
institutional trial designed to assess the toxicity and feasibility
of EBRT plus LDR brachytherapy boost (45Gy/25 fractions +
100Gy 125I or 90Gy 103Pd boost) combined with 6 months of
ADT (41). Acute Grade 2 and 3 toxicity occurred in 25 and
7% of men and was most commonly urinary frequency/urgency
(41). Late Grade 2 and 3 toxicity was observed in 20% and
2% of men, respectively (41). Differences between these two
multi-institutional protocols included an expansion on the LDR
boost clinical target volume (CTV) of 5mm (0mm posteriorly)
in the RTOG trial compared to no expansion in the CALGB
trial, which may contribute to the rates of late Grade 3 or
greater toxicities.
In the randomized ASCENDE-RT trial, toxicity was increased
in the brachytherapy group with the cumulative incidence of
grade 3 GU events at 5 years of ∼18% for the brachytherapy
boost arm vs. 5% for the EBRT alone arm (p < 0.001). There
was also a trend toward increased gastrointestinal toxicity with
the brachytherapy boost, 8 vs. 3% (p = 0.12) (42). However,
at the 6-years follow-up time point, health-related quality of
life was similar between the two groups in most domains with
the exception that physical and urinary function scales were
lower in the LDR arm (43). Regardless, the increased toxicity
observed in the combined EBRT plus LDR boost armASCENDE-
RT highlights the importance of careful patient selection and
diligent treatment planning as well as early intervention with
symptom management as needed for these patients. A detailed
analysis of the treatment related morbidity from the trial is
available (42).
HDR brachytherapy may be a method to overcome the
acute toxicities seen with LDR given the physical properties of
this treatment modality. With an LDR implant, the radiation
dose is delivered over a time period of months compared to
minutes with HDR. For this reason, LDR is associated with a
more prolonged recovery period. A prospective non-randomized
comparison of quality of life after LDR vs. HDR boost (combined
with 4.5 weeks of EBRT) showed a return to baseline IPSS at 6
months with LDR compared to only 12 weeks with HDR (44).
Another early analysis of a randomized controlled trial of HDR
vs. LDR in the monotherapy setting suggests improved quality
of life, shorter return time to baseline urinary function, and
lower rates of acute urinary symptoms with HDR monotherapy
(45). While the previous studies show very favorable toxicity
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profiles with HDR brachytherapy compared to LDR, HDR
has been associated with non-insignificant rates of urethral
stricture. In a study by Bece et al. reported in 2015, various
doses and fractionations of HDR boost (19.5Gy/3fractions;
17Gy/2 fractions; 18Gy/2 fractions; and 19Gy/2 fractions) in
combination with EBRT were used and overall 3 and 6-years
stricture incidence were 7.8 and 15.3%, respectively (46). The
HDR boost fractionation scheme evolved during their study and
the most recent fractionation used (19Gy/2 fractions) resulted
in the lowest three-year stricture rate of 3.0% (46). Yaxley et
al. retrospectively analyzed a series of 507 men consecutively
treated with EBRT plus HDR brachytherapy with a median
follow-up of 10.3 years and found that rates of urethral stricture
can be significantly reduced with careful attention to dose
heterogeneity constraints, imaging prior to second HDR fraction
to control for needle displacement, and tighter apical (inferior)
PTV margins during the EBRT (47). Prior to implementation of
these “stricture prevention measures,” the rate of stricture was
13.6% and this rate dramatically fell to 4.2% using these planning
considerations (47).
In terms of long-term toxicity, an investigation using the
Surveillance, Epidemiology, and End Results Medicare database
(SEER) did not show a statistically significant difference in
Grade 3 genitourinary adverse events between LDR and HDR
(48). The results of the BrachyQOL randomized controlled trial
(NCT01936883) are highly anticipated as they will shed more
definitive light on both the acute and late GU/GI side-effect
profiles between LDR and HDR in the boost setting (49).
DECLINING USE OF BRACHYTHERAPY
BOOST
Despite potential improved outcomes with either LDR or HDR
boost, the rates of brachytherapy boost utilization are declining
(50, 51). Multiple reasons for the declining use of a boost
have been reported including increase of prostatectomies for
higher risk patients (52), increases in reimbursement for other
EBRT techniques (53), decrease in brachytherapy training (54),
and potential perception that brachytherapy is a procedure
with excessive liability risk (51). In an analysis by Johnson et
al. (19), the utilization of LDR brachytherapy boost dropped
from ∼29% in 2004 to 14% in 2012. Previous database-based
studies also report the declining use of EBRT plus brachytherapy
boost (52). The American Brachytherapy Society (ABS) has
started a “300 in 10” initiative to increase the training of
brachytherapists by assisting in the training of 30 oncologists
per year over a 10-years period. Initiatives such as this are
extremely important as a brachytherapy boost has the potential
to improve prostate-specific survival outcomes when compared
to EBRT alone.
FUTURE DIRECTIONS
While an optimal dose for LDR brachytherapy boost has been
established, studies continue to determine the optimal HDR
schedule and dose escalation continues to be investigated in
the HDR setting. Also, limited data on prostate cancer specific
survival outcomes between HDR and LDR exist. The British
Columbia Cancer Agency is conducting a Phase III randomized
controlled trial in patients with unfavorable intermediate risk
and high-risk prostate cancer who will receive 46Gy in 23
fractions of EBRT and then be randomized to either a LDR
boost using 125I (115Gy) or HDR boost using 192Ir (15Gy x
1). In addition to quality of life measures, a secondary outcome
is PSA recurrence-free survival which will provide randomized
head-to-head outcomes between LDR and HDR brachytherapy
boost. Another unknown for both LDR and HDR boost in
the high risk setting is defining the optimal planning target
volume (PTV) to balance tumor coverage while minimizing
toxicity. The differences in CTV to PTV expansion between
RTOG 0019 and CALBG 99809 in the intermediate risk setting
were 5 vs. 0mm, respectively, and may have long term toxicity
consequences. In high-risk prostate cancer, while the external
beam target volumes should include any extracapsular extension
and the at risk proximal seminal vesicles, some intuitions are
including both the proximal seminal vesicles and extracapsular
extension in the brachytherapy boost volume, but the clinical
significance of such inclusion is unknown. Advanced computer
planning and CT/MRI/Ultrasound-based planning with HDR
brachytherapy may allow better and more reproducible coverage
of the seminal vesicles and extracapsular extension compared
to LDR given the inherent post-implant treatment planning
capabilities with HDR. Additionally, as imaging technology
continues to improve, small institutional trials are underway
or have completed investigating focal brachytherapy boost to
intraprostatic lesions using MRI-transrectal-ultrasound fusion
(55). Lastly, SBRT continues to gain popularity given its shorter
treatment course and less invasive nature, comparisons between
SBRT and brachytherapy are emerging. Preliminary data from a
reported literature search of 47 studies on PubMed and Embase
(6 SBRT boost and 41 HDR boost), showed that a SBRT boost
may be associated with higher acute Grade 2 genitourinary
toxicity but lower late Grade 3 GU toxicity, and no difference
was seen between the two by quality of life reports. Randomized
trials between both LDR and HDR boost and SBRT boost are
warranted and underway.
CONCLUSIONS
Both HDR and LDR brachytherapy provide a method of
biologically equivalent dose escalation in patients with high-
risk prostate cancer who are undergoing definitive intent
radiation therapy. In combination with EBRT, brachytherapy
is a modality to deliver highly conformal dose escalation
while drastically sparing the rectum and bladder compared
to EBRT alone. Two randomized controlled trials have
shown improved biochemical control with EBRT plus
brachytherapy boost but neither demonstrated a statistical
difference in overall survival (16, 25). The LDR boost
arm in the ASCENDE-RT trial demonstrated a significant
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improvement in biochemical progression-free survival and
long term survival outcomes are eagerly anticipated (9).
Despite the improvements in biochemical control with
brachytherapy boost, trends in the use of brachytherapy
continue to decline nationally, possibly secondary to concerns
of acute genitourinary toxicity with LDR. Initiatives to
increase brachytherapy use are currently underway, and
HDR brachytherapy may be an opportunity to improve toxicity
profiles while exploiting the radiobiology of prostate cancer in
the boost setting.
AUTHOR CONTRIBUTIONS
BF-V, HG, SP, BB, and JM: literature search, writing, and
final approval.
SUPPLEMENTARY MATERIAL




1. Siegel RL,Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019)
69:7–34. doi: 10.3322/caac.21551
2. Mohler JL, Antonarakis ES. NCCN guidelines updates: management
of prostate cancer. J Natl Compr Canc Netw. (2019) 17:583–6.
doi: 10.6004/jnccn.2019.5011
3. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary
JP, et al. Effect of standard vs. dose-escalated radiation therapy for
patients with intermediate-risk prostate cancer: the NRG oncology
RTOG 0126 randomized clinical trial. JAMA Oncol. (2018) 4:e180039.
doi: 10.1001/jamaoncol.2018.0039
4. Trada Y, Plank A, Martin J. Defining a dose-response relationship for prostate
external beam radiotherapy. J Med Imaging Radiat Oncol. (2013) 57:237–46.
doi: 10.1111/1754-9485.12008
5. Pryor D, Sidhom M, Arumugam S, Bucci J, Gallagher S, Smart J, et al.
Phase 2 multicenter study of gantry-based stereotactic radiotherapy boost for
intermediate and high risk prostate cancer (PROMETHEUS). Front Oncol.
(2019) 9:217. doi: 10.3389/fonc.2019.00217
6. Zaorsky NG, Keith SW, Shaikh T, Nguyen PL, Horwitz EM, Dicker
AP, et al. Impact of radiation therapy dose escalation on prostate
cancer outcomes and toxicities. Am J Clin Oncol. (2018) 41:409–15.
doi: 10.1097/COC.0000000000000285
7. Mendez LC, Morton GC. High dose-rate brachytherapy in the
treatment of prostate cancer. Transl Androl Urol. (2018) 7:357–70.
doi: 10.21037/tau.2017.12.08
8. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, et al.
Brachytherapy for patients with prostate cancer: American society of clinical
oncology/cancer care ontario joint guideline update. J Clin Oncol. (2017)
35:1737–43. doi: 10.1200/JCO.2016.72.0466
9. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al.
Androgen suppression combined with elective nodal and dose escalated
radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints
for a randomized trial comparing a low-dose-rate brachytherapy boost
to a dose-escalated external beam boost for high- and intermediate-
risk prostate cancer. Int J Radiat Oncol Biol Phys. (2017) 98:275–85.
doi: 10.1016/j.ijrobp.2016.11.026
10. Wang Y, Sankreacha R, Al-Hebshi A, Loblaw A, Morton G. Comparative
study of dosimetry between high-dose-rate and permanent prostate implant
brachytherapies in patients with prostate adenocarcinoma. Brachytherapy.
(2006) 5:251–5. doi: 10.1016/j.brachy.2006.08.006
11. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson
GS. High-dose-rate prostate brachytherapy: an excellent accelerated-
hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol.
(2010) 33:481–8. doi: 10.1097/COC.0b013e3181b9cd2f
12. International Commission on Radiological Units and Measurements. Dose
and Volume Specifications for Reporting Intracavitary Therapy in Gynecology.
ICRU report 38 (ICRU).
13. Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, et
al. Long-term outcome for clinically localized prostate cancer treated with
permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. (2011)
79:1336–42. doi: 10.1016/j.ijrobp.2010.01.005
14. Crook J, Borg J, Evans A, Toi A, Saibishkumar EP, Fung S, et al. 10-
year experience with I-125 prostate brachytherapy at the Princess Margaret
Hospital: results for 1,100 patients. Int J Radiat Oncol Biol Phys. (2011)
80:1323–9. doi: 10.1016/j.ijrobp.2010.04.038
15. Marshall RA, Buckstein M, Stone NN, Stock R. Treatment outcomes
and morbidity following definitive brachytherapy with or without external
beam radiation for the treatment of localized prostate cancer: 20-years
experience at Mount Sinai Medical Center. Urol Oncol. (2014) 32:38 e1–7.
doi: 10.1016/j.urolonc.2013.03.004
16. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al.
Randomized trial comparing iridium implant plus external-beam radiation
therapy with external-beam radiation therapy alone in node-negative
locally advanced cancer of the prostate. J Clin Oncol. (2005) 23:1192–9.
doi: 10.1200/JCO.2005.06.154
17. Dayes IS, Parpia S, Gilbert J, Julian JA, Davis IR, Levine MN, et al. Long-term
results of a randomized trial comparing iridium implant plus external beam
radiation therapy with external beam radiation therapy alone in node-negative
locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys. (2017)
99:90–3. doi: 10.1016/j.ijrobp.2017.05.013
18. Muralidhar V, Xiang M, Orio PF III, Martin NE, Beard CJ, Feng FY, et
al. Brachytherapy boost and cancer-specific mortality in favorable high-risk
versus other high-risk prostate cancer. J Contemp Brachytherapy. (2016) 8:1–6.
doi: 10.5114/jcb.2016.58080
19. Johnson SB, Lester-Coll NH, Kelly JR, Kann BH, Yu JB, Nath SK.
Brachytherapy boost utilization and survival in unfavorable-risk prostate
cancer. Eur Urol. (2017) 72:738–44. doi: 10.1016/j.eururo.2017.06.020
20. Stish BJ, Davis BJ, Mynderse LA, McLaren RH, Deufel CL, Choo R. Low
dose rate prostate brachytherapy. Transl Androl Urol. (2018) 7:341–56.
doi: 10.21037/tau.2017.12.15
21. King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate
cancer: predictions for conventional external beam, IMRT, and brachytherapy
from radiobiologic models. Int J Radiat Oncol Biol Phys. (2000) 46:165–72.
doi: 10.1016/S0360-3016(99)00406-X
22. King CR. LDR vs. HDR brachytherapy for localized prostate cancer:
the view from radiobiological models. Brachytherapy. (2002) 1:219–26.
doi: 10.1016/S1538-4721(02)00101-0
23. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of
prostate carcinoma. Int J Radiat Oncol Biol Phys. (1999) 43:1095–101.
doi: 10.1016/S0360-3016(98)00438-6
24. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour
EP. Direct evidence that prostate tumors show high sensitivity to fractionation
(low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat
Oncol Biol Phys. (2002) 52:6–13. doi: 10.1016/S0360-3016(01)02664-5
25. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised
trial of external beam radiotherapy alone or combined with high-dose-rate
brachytherapy boost for localised prostate cancer. Radiother Oncol. (2012)
103:217–22. doi: 10.1016/j.radonc.2012.01.007
26. Vigneault E, Morton G, Parulekar WR, Niazi TM, Springer CW, Barkati M,
et al. Randomised phase II feasibility trial of image-guided external beam
radiotherapy with or without high dose rate brachytherapy boost in men with
intermediate-risk prostate cancer (CCTG PR15/NCT01982786). Clin Oncol.
(2018) 30:527–33. doi: 10.1016/j.clon.2018.05.007
Frontiers in Oncology | www.frontiersin.org 6 December 2019 | Volume 9 | Article 1378
Fischer-Valuck et al. Brachytherapy Boost High-Risk Prostate Cancer
27. Vigneault E, Mbodji K, Magnan S, Despres P, Lavallee MC, Aubin S, et al.
High-dose-rate brachytherapy boost for prostate cancer treatment: different
combinations of hypofractionated regimens and clinical outcomes. Radiother
Oncol. (2017) 124:49–55. doi: 10.1016/j.radonc.2017.06.012
28. Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, et al. Dose
escalation improves cancer-related events at 10 years for intermediate- and
high-risk prostate cancer patients treated with hypofractionated high-dose-
rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys. (2011)
79:363–70. doi: 10.1016/j.ijrobp.2009.10.035
29. Kent AR, Matheson B, Millar JL. Improved survival for patients
with prostate cancer receiving high-dose-rate brachytherapy boost to
EBRT compared with EBRT alone. Brachytherapy. (2019) 18:313–21.
doi: 10.1016/j.brachy.2019.01.013
30. Borghede G, Hedelin H, Holmang S, Johansson KA, Aldenborg F, Pettersson
S, et al. Combined treatment with temporary short-term high dose rate
iridium-192 brachytherapy and external beam radiotherapy for irradiation
of localized prostatic carcinoma. Radiother Oncol. (1997) 44:237–44.
doi: 10.1016/S0167-8140(97)00121-7
31. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney
D, et al. Conformal high dose rate brachytherapy improves biochemical
control and cause specific survival in patients with prostate cancer
and poor prognostic factors. J Urol. (2003) 169:974–9; discussion 9–80.
doi: 10.1097/01.ju.0000052720.62999.a9
32. Galalae RM, Loch T, Riemer B, Rzehak P, Kuchler T, Kimmig B, et al. Health-
related quality of life measurement in long-term survivors and outcome
following radical radiotherapy for localized prostate cancer. Strahlenther
Onkol. (2004) 180:582–9. doi: 10.1007/s00066-004-1254-x
33. Duchesne GM, Williams SG, Das R, Tai KH. Patterns of toxicity
following high-dose-rate brachytherapy boost for prostate cancer: mature
prospective phase I/II study results. Radiother Oncol. (2007) 84:128–34.
doi: 10.1016/j.radonc.2007.05.019
34. Kalkner KM, Wahlgren T, Ryberg M, Cohn-Cedermark G, Castellanos E,
Zimmerman R, et al. Clinical outcome in patients with prostate cancer
treated with external beam radiotherapy and high dose-rate iridium 192
brachytherapy boost: a 6-year follow-up. Acta Oncol. (2007) 46:909–17.
doi: 10.1080/02841860601156140
35. Shah C, Lanni TB Jr, Ghilezan MI, Gustafson GS, Marvin KS, Ye
H, et al. Brachytherapy provides comparable outcomes and improved
cost-effectiveness in the treatment of low/intermediate prostate cancer.
Brachytherapy. (2012) 11:441–5. doi: 10.1016/j.brachy.2012.04.002
36. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al.
Comparative analysis of prostate-specific antigen free survival outcomes for
patients with low, intermediate and high risk prostate cancer treatment by
radical therapy. Results from the Prostate Cancer Results Study Group. BJU
Int. (2012) 109 (Suppl. 1):22–9. doi: 10.1111/j.1464-410X.2011.10827.x
37. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL,
et al. Radical prostatectomy, external beam radiotherapy, or external beam
radiotherapy with brachytherapy boost and disease progression and mortality
in patients with gleason score 9-10 prostate cancer. JAMA. (2018) 319:896–
905. doi: 10.1001/jama.2018.0587
38. King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, et al. A
comparative analysis of overall survival between high-dose-rate and low-dose-
rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy.
(2019) 18:186–91. doi: 10.1016/j.brachy.2018.12.007
39. Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, et al. A phase
II study of external beam radiotherapy combined with permanent source
brachytherapy for intermediate-risk, clinically localized adenocarcinoma of
the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys.
(2006) 64:804–9. doi: 10.1016/j.ijrobp.2005.09.002
40. Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, et al.
Late toxicity and biochemical recurrence after external-beam radiotherapy
combined with permanent-source prostate brachytherapy: analysis of
Radiation Therapy Oncology Group study 0019. Cancer. (2007) 109:1506–12.
doi: 10.1002/cncr.22560
41. Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase
SJ, et al. Combination external beam radiation and brachytherapy boost
with androgen deprivation for treatment of intermediate-risk prostate
cancer: long-term results of CALGB 99809. Cancer. (2011) 117:5579–88.
doi: 10.1002/cncr.26203
42. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al.
ASCENDE-RT: an analysis of treatment-related morbidity for a randomized
trial comparing a low-dose-rate brachytherapy boost with a dose-escalated
external beam boost for high- and intermediate-risk prostate cancer. Int
J Radiat Oncol Biol Phys. (2017) 98:286–95. doi: 10.1016/j.ijrobp.2017.
01.008
43. Rodda S, Morris WJ, Hamm J, Duncan G. ASCENDE-RT: an analysis
of health-related quality of life for a randomized trial comparing
low-dose-rate brachytherapy boost with dose-escalated external
beam boost for high- and intermediate-risk prostate cancer. Int J
Radiat Oncol Biol Phys. (2017) 98:581–9. doi: 10.1016/j.ijrobp.2017.
02.027
44. Rose TGE, Bachand F, Kim D. QOL comparison of acute side effects
from a high dose rate vs. low dose rate brachytherapy boost combined
with external beam radiotherapy. Brachytherapy. (2015) 14:S36.
doi: 10.1016/j.brachy.2015.02.245
45. Hathout L, Mahmoud O, Barkati M, Despres P, Mbodjii K, Martin AG, et al.
A phase II randomized pilot study comparing high-dose rate brachytherapy
and low-dose rate brachytherapy as monotherapy in localized prostate cancer.
Brachytherapy. (2018) 17:S56–S5. doi: 10.1016/j.brachy.2018.04.090
46. Bece A, Patanjali N, Jackson M, Whitaker M, Hruby G. High-dose-rate
brachytherapy boost for prostate cancer: outcomes and genitourinary toxicity.
Brachytherapy. (2015) 14:670–6. doi: 10.1016/j.brachy.2015.04.004
47. Yaxley JW, Lah K, Yaxley JP, Gardiner RA, Samaratunga H, MacKean J. Long-
term outcomes of high-dose-rate brachytherapy for intermediate- and high-
risk prostate cancer with a median follow-up of 10 years. BJU Int. (2017)
120:56–60. doi: 10.1111/bju.13659
48. Tward JD, Jarosek S, Chu H, Thorpe C, Shrieve DC, Elliott S. Time
course and accumulated risk of severe urinary adverse events after high-
versus low-dose-rate prostate brachytherapy with or without external
beam radiation therapy. Int J Radiat Oncol Biol Phys. (2016) 95:1443–53.
doi: 10.1016/j.ijrobp.2016.03.047
49. Improving quality of life after prostate brachytherapy: a comparison of HDR
and LDR brachytherapy. https://clinicaltrials.gov/ct2/show/NCT01936883.
50. Barnes J, KennedyWR, Fischer-Valuck BW, Baumann BC, Michalski JM, Gay
HA. Treatment patterns of high-dose-rate and low-dose-rate brachytherapy
as monotherapy for prostate cancer. J Contemp Brachyther. (2019) 11:320–8.
doi: 10.5114/jcb.2019.86974
51. Petereit DG, Frank SJ, Viswanathan AN, Erickson B, Eifel P, Nguyen PL,
et al. Brachytherapy: where has it gone? J Clin Oncol. (2015) 33:980–2.
doi: 10.1200/JCO.2014.59.8128
52. Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM,
et al. The rise and fall of prostate brachytherapy: use of brachytherapy for
the treatment of localized prostate cancer in the National Cancer Data Base.
Cancer. (2014) 120:2114–21. doi: 10.1002/cncr.28697
53. Mitchell JM. Urologists’ use of intensity-modulated radiation
therapy for prostate cancer. N Engl J Med. (2013) 369:1629–37.
doi: 10.1056/NEJMsa1201141
54. Compton JJ, Gaspar LE, Shrieve DC, Wilson LD, Griem KL, Amdur RJ,
et al. Resident-reported brachytherapy experience in ACGME-accredited
radiation oncology training programs. Brachytherapy. (2013) 12:622–7.
doi: 10.1016/j.brachy.2013.06.004
55. Gomez-Iturriaga A, Casquero F, Urresola A, Ezquerro A, Lopez JI,
Espinosa JM, et al. Dose escalation to dominant intraprostatic lesions
with MRI-transrectal ultrasound fusion High-Dose-Rate prostate
brachytherapy. Prospective phase II trial. Radiother Oncol. (2016) 119:91–6.
doi: 10.1016/j.radonc.2016.02.004
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Fischer-Valuck, Gay, Patel, Baumann and Michalski. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Oncology | www.frontiersin.org 7 December 2019 | Volume 9 | Article 1378
